-
Dr. Jun Cao: Enhancing Quality of Life in HR⁺ Breast Cancer—Entinostat Offers Patients a Path Back to Normalcy
As treatment options for hormone receptor-positive (HR⁺) breast cancer continue to diversify—from chemotherapy and endocrine therapy to targeted treatments—survival outcomes are improving. However, alongside extended survival, maintaining quality of life (QoL) and enabling patients to return to everyday life have become equally vital goals. Entinostat, a novel histone deacetylase inhibitor (HDACi), stands out with its…
-
Dr. Peifen Fu: Breaking the Barrier of Endocrine Resistance in HR⁺ Breast Cancer with a Novel HDAC Inhibitor
Hormone receptor-positive (HR+) breast cancer accounts for approximately 70% of all breast cancer cases and remains the most prevalent subtype. While endocrine therapy continues to serve as the cornerstone of HR+ breast cancer treatment, and CDK4/6 inhibitors (CDK4/6i) have become standard in both early and advanced settings, resistance to therapy remains a formidable clinical challenge.…
-
Dr. Xiaojia Wang: With Overall Survival Exceeding 38 Months, HDAC Inhibition Redefines Second-Line Treatment for HR⁺ Advanced Breast Cancer
Breast cancer remains one of the leading malignancies threatening women’s health worldwide. Among its various subtypes, hormone receptor-positive (HR⁺) breast cancer is the most prevalent, comprising about 70% of all cases. While the advent of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has become the gold standard for first-line treatment of HR⁺/HER2⁻ advanced breast…
-
Dr. Yanxia Shi: In the Post-CDK4/6i Era, Entinostat Emerges as a Promising Treatment Option for HR+/HER2- MBC Patients
With the continuous advancement of pharmaceutical and medical technologies, novel therapies have steadily extended survival for breast cancer patients. Among them, the combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) has brought transformative improvements in outcomes for patients with hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer (MBC). Despite its establishment as the current standard first-line…
-
Dr. Jiahong Dong: APASL 2025 BEIJING——Drawing a Blueprint for Liver Disease Elimination and Cure Through Multidisciplinary Collaboration
Liver diseases remain a global challenge with complex diagnostic and therapeutic hurdles. Addressing these requires not only pooling the expertise of global specialists but also integrating valuable experiences from both Eastern and Western medical practices.
-
Dr. Peng Yuan: In the Post-CDK4/6i Era, Entinostat Offers New Hope for Patients with HR+/HER2− Advanced Breast Cancer
Breast cancer remains one of the most prevalent malignancies among women worldwide, and its hormone receptor-positive, HER2-negative (HR+/HER2−) subtype accounts for nearly 70% of all cases. In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has become the gold standard for first-line treatment in metastatic settings. However, once progression occurs on…
-
Dr. Jian Zhang: How Emerging HDAC Inhibitors Could Transform the Treatment Landscape of HR+ Breast Cancer
The recent approval in China of the HDAC inhibitor entinostat introduces a novel, precision-targeted approach to breast cancer treatment. Unlike many targeted therapies, entinostat does not require biomarker testing before…
-
Dr. Nanlin Li: Reshaping the Breast Cancer Treatment Landscape — Clinical Practice and Future Outlook of Weekly HDACi Entinostat
On April 24, 2024, a major milestone was achieved in China’s oncology landscape. The National Medical Products Administration (NMPA) granted official approval for entinostat, a domestically developed, selective histone deacetylase…
Connecting Medical Expertise through Media